Sep 7, 2026 – 3.01pmFormer Merrill Lynch banker David Bottomley says he first became aware of the premiums global medical device firms were willing to pay for Australian science while overseeing a string of healthcare deals two decades ago.Despite the success of stand-outs like hearing implant maker Cochlear, medical technology, or medtech, is a notoriously complex sector and struggles to attract the same level of funding as the biotech industry, where the returns are far higher, but so are the risks of failure.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles
Surgeon investors look to cash in on medical technology start-ups
Medtech, an often-overlooked poorer cousin to biotech, is attracting investment dollars from practitioners who can see the value in efficiency-saving devices.
104 words~1 min read
